Study findings in patients with rheumatoid arthritis (RA), write the authors, suggest “that potentially more aggressive treatment is needed across the entire population of patients with RA."
While guidelines recommend that patients with rheumatoid arthritis (RA) who do not have an adequate response to conventional disease-modifying antirheumatic drugs (DMARDs) be treated with biologics or Janus kinase (JAK) inhibitors, it remains common in clinical practice that patients remain in moderate or high disease activity without gaining access to more effective therapies.
Recently, researchers reported on the disease burden among patients with RA who did not advance to a biologic to treat their disease, and they found a considerable need for a treat-to-target approach.
The researchers used data from the Corrona RA registry, an independent, prospective, observational cohort of patients with RA that began in 2001. As of 2018, the registry included data from approximately 50,600 adult patients.
The research team used data for the 2982 biologic-naïve patients enrolled as of 2014 who had been taking conventional DMARDs for at least 6 moths. There were 414 patients who completed a follow-up visit at 3 to 9 months; 409 had Clinical Disease Activity Index (CDAI) assessments at 6 months.
Despite therapy with DMARDs for at least 6 months, 54% of patients with a CDAI assessment had persistent moderate to severe disease activity. These patients had higher baseline swollen and tender joint counts than patients who were in remission or who had low disease activity at 6 months.
Over the 6-month period, treatment advancement occurred for 29% of patients, and those who advanced to a new treatment were younger, had a shorter duration of RA, had higher disease activity, and reported higher levels of fatigue and pain than patients who did not advance to a new therapy.
These findings, write the authors, suggest “that potentially more aggressive treatment is needed across the entire population of patients with RA. Consistent with the findings in this study, patient factors, such as disease duration, disease activity, and work status, have been described elsewhere as contributing to patients receiving care in line with treatment recommendations.”
Future studies are needed, they add, to better examine factors related to the response variation to DMARDs and treatment selection for RA.
Reference
Harrold LR, Patel PA, Griffith J, et al. Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona registry [published online October 21, 2019]. Clin Rheumatol. doi: 10.1007/s10067-019-04727-7.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.